Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message

Journal of Clinical Oncology

Volumn 19, Issue 10, 2001, Pages 2714-2721

  Tubbs, Raymund R ^b   Pettay, J D ^c   Roche, P C ^c   Stoler, M H ^c   Jenkins, R B ^c   Grogan, T M ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIGITOXIGENIN; MESSENGER RNA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL LABORATORY; CONTROLLED STUDY; DNA RNA HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; ONCOGENE NEU; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RNA RNA HYBRIDIZATION; TRANSCRIPTION REGULATION;

EID: 0035873962     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.10.2714     Document Type: Article

References (28)

1. American Cancer Society: Statistics: Cancer Facts and Figures - Selected Cancers: Breast. Http://www.cancer.org.
2. Toikkanen S, Helin H, Isola J, et al: Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up, J Clin Oncol 10:1044-1048, 1992
3. Seshadri R, Firgaria FA, Horsfall DJ, et al: Clinical significance of Her-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11:1936-1942, 1993
4. Ro J, El-Naggar A, Ro J: C-erb B-2 amplification in node-negative human breast cancer. Cancer Res 49:6941-6944, 1989
5. Slamon DJ, Godolphin W, Jones L, et al: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
6. Tsuda H, Hirohashi S, Shimosato, et al: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene coamplification units: hst-1 1/int-2 and c-erb B-2/er-1. Cancer Res 49:3104-3108, 1989
7. Kallioniemi OP, Holli K, Visakorpi T, et al: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
8. Babiak J, Hugh J, Poppema S: Significance of c-erbB-2 amplification and DNA aneuploidy: Analysis in 78 patients with node-negative breast cancer. Cancer 70:770-776, 1992
9. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997
10. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
11. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
12. Cobleigh MA, Vogle CL, Tripath D, et al: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr 376)
13. Slamon D, Leyland-Jones B, Shak S: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998 (abstr 377)
14. Thor AD, Berry DA, Budman DR, et al: erbB2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998
15. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
16. Bianco AR, De Laurentiis M, Carlomagno C: 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr 393)
17. Gusterson BA, Gelbert RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
18. Jimenez RE, Wallis T, Tabasczka P, et al: Determination of Her-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization (FISH). Mod Pathol 13:27-45, 2000
19. Press MF, Hung G, Godolphin W, et al: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
20. Vang R, Cooley LD, Harrison WR, et al: Immunohistochemical determination of Her-2/neu expression in invasive breast carcinoma. Am J Clin Pathol 113:669-674, 2000
21. Gancberg D, Lespagnard L, Rouas G, et al: Sensitivity of Her-2/neu antibodies in archival tissue samples of invasive breast carcinomas: Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 113:675-682, 2000
22. Pauletti G, Godolpin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72, 1996
23. Jacobs TW, Gown AM, Yaziji H, et al: Specificity of HercepTest in determining Her-2/neu status of breast cancer using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17:1983-1987, 1999
24. Roche PC, Ingle JN: Increased Her-2 with US Food and Drug Administration approved antibody. J Clin Oncol 17:434-435, 1999
25. Roche PC: HER2/neu. CAP Today, Northfield, IL, June 1999, p 16
26. Segal GH, Schick HE, Tubbs RR, et al: In situ hybridization analysis of lymphoproliferative disorders: Assessment of clonality by immunoglobulin light-chain messenger RNA expression. Diagn Mol Pathol 3:170-177, 1994
27. Tubbs RR, Pettay J, Roche P, et al: Concomitant oncoprotein detection and fluorescence in situ hybridization (CODFISH): A fluorescence based assay enabling simultaneous visualization of gene amplification and encoded protein expression. J Mol Diagnost 2:78-83, 2000
28. Tubbs RR, Stoler MH: The quality of Her-2/neu predictive immunohistochemistry: Something FISHy? Mod Pathol 13:1-3, 2000